argenx SE – American Depositary Shares (ARGX) Downgraded by Zacks Investment Research

argenx SE – American Depositary Shares (NASDAQ:ARGX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Friday.

According to Zacks, “argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands. “

Several other equities research analysts have also issued reports on the stock. Wedbush reiterated an “outperform” rating and set a $41.00 target price (up from $26.00) on shares of argenx SE – American Depositary Shares in a research report on Thursday, November 16th. They noted that the move was a valuation call. Piper Jaffray Companies lifted their target price on shares of argenx SE – American Depositary Shares to $100.00 and gave the company an “overweight” rating in a research report on Tuesday, December 19th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. argenx SE – American Depositary Shares presently has an average rating of “Buy” and an average target price of $62.75.

Shares of argenx SE – American Depositary Shares (ARGX) traded up $1.05 during trading on Friday, reaching $66.33. 179,483 shares of the company’s stock traded hands, compared to its average volume of 239,453. argenx SE – American Depositary Shares has a twelve month low of $17.33 and a twelve month high of $71.40.

A number of institutional investors have recently made changes to their positions in the business. Nicholas Investment Partners LP bought a new stake in shares of argenx SE – American Depositary Shares in the 2nd quarter worth approximately $236,000. DAFNA Capital Management LLC bought a new stake in shares of argenx SE – American Depositary Shares in the 2nd quarter worth approximately $848,000. Artal Group S.A. bought a new stake in shares of argenx SE – American Depositary Shares in the 3rd quarter worth approximately $1,229,000. Tekla Capital Management LLC bought a new stake in shares of argenx SE – American Depositary Shares in the 2nd quarter worth approximately $1,591,000. Finally, AWM Investment Company Inc. bought a new stake in shares of argenx SE – American Depositary Shares in the 2nd quarter worth approximately $2,121,000. Institutional investors and hedge funds own 21.59% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/19/argenx-se-american-depositary-shares-argx-downgraded-by-zacks-investment-research.html.

About argenx SE – American Depositary Shares

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Get a free copy of the Zacks research report on argenx SE – American Depositary Shares (ARGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for argenx SE - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx SE - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply